Search all trials

Find therapies in clinical trials near you

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 961
countries: 28
conditions: 2 103

3 961 trials recruiting28 European countries2 103 conditions coveredUpdated today

Quick filters

Metastatic malignant melanoma+2

Recruiting

InvestigationalNo placebo

Long-term Safety Study of Vusolimogene Oderparepvec, RP2, and RP3 in Patients with Melanoma, Liver Cancer, or Advanced Solid Tumors

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:RP2

Contact Research Centre

Metastatic malignant melanoma

Recruiting

Registered drugNo placebo

Study of TIL therapy combined with peginterferon alfa-2a and nivolumab for patients with metastatic melanoma

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:TIL CELLS

Contact Research Centre

Metastatic malignant melanoma+1

Recruiting

Registered drugNo placebo

Long-Term Safety Study of Dabrafenib Mesylate and Trametinib Dimethyl Sulfoxide for Patients Benefiting from Previous Treatment in Multiple Indications

Registered drugNo placebo

Austria

Participants:0–17 years · 18–64 years · 65+ years
Substances:Dabrafenib Mesylate

Contact Research Centre

Metastatic malignant melanoma

Recruiting

Registered drugNo placebo

Study on Adding Diclofenac to PD-1 Inhibitor Therapy for Patients with Metastatic Melanoma

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Diclofenac Sodium

Contact Research Centre

Metastatic malignant melanoma

Recruiting

InvestigationalNo placebo

Study Comparing Subcutaneous and Intravenous Nivolumab and Relatlimab for Patients with Untreated Metastatic or Unresectable Melanoma

InvestigationalNo placebo

Austria

Participants:0–17 years · 18–64 years · 65+ years
Substances:Nivolumab

Contact Research Centre

Metastatic malignant melanoma+1

Recruiting

Registered drugNo placebo

Study of Tebentafusp and Pembrolizumab for Patients with Previously Treated Advanced Melanoma

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Dexamethasone

Contact Research Centre

Metastatic malignant melanoma

Not yet recruiting

Registered drugNo placebo

Methoxsalen (ECP) versus drug combination for steroid‑refractory immune‑related colitis or hepatitis in metastatic melanoma on checkpoint therapy

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Azathioprine

Contact Research Centre

Metastatic malignant melanoma+2

Not recruiting

Registered drugNo placebo

Study of local treatment options for large metastases in patients with BRAF V600 mutated melanoma receiving Encorafenib and Binimetinib combination therapy

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Binimetinib

Contact Research Centre

Metastatic malignant melanoma

Not recruiting

Registered drugNo placebo

Study on the Effectiveness of Enfortumab Vedotin and Pembrolizumab for Patients with Advanced Melanoma

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Enfortumab Vedotin

Contact Research Centre

Metastatic malignant melanoma

Not recruiting

Registered drugNo placebo

Study of BI-1607, Ipilimumab, and Pembrolizumab for Patients with Advanced Melanoma

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:BI-1607

Contact Research Centre

Metastatic malignant melanoma

Not recruiting

Registered drugNo placebo

Study Comparing ABP 206 and Nivolumab for Patients with Unresectable or Metastatic Melanoma

Registered drugNo placebo

Croatia

Participants:18–64 years · 65+ years
Substances:Nivolumab

Contact Research Centre

Metastatic malignant melanoma

Not recruiting

Registered drugNo placebo

Study on Dacarbazine, Pembrolizumab, Nivolumab, and Ipilimumab for Patients with Unresectable or Metastatic Melanoma Resistant to Immunotherapy

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Dacarbazine

Contact Research Centre

Find therapies in clinical trials near you

32 trials match your criteria

Metastatic malignant melanoma+2

Long-term Safety Study of Vusolimogene Oderparepvec, RP2, and RP3 in Patients with Melanoma, Liver Cancer, or Advanced Solid Tumors

Metastatic malignant melanoma

Study of TIL therapy combined with peginterferon alfa-2a and nivolumab for patients with metastatic melanoma

Metastatic malignant melanoma+1

Long-Term Safety Study of Dabrafenib Mesylate and Trametinib Dimethyl Sulfoxide for Patients Benefiting from Previous Treatment in Multiple Indications

Metastatic malignant melanoma

Study on Adding Diclofenac to PD-1 Inhibitor Therapy for Patients with Metastatic Melanoma

Metastatic malignant melanoma

Study Comparing Subcutaneous and Intravenous Nivolumab and Relatlimab for Patients with Untreated Metastatic or Unresectable Melanoma

Metastatic malignant melanoma+1

Study of Tebentafusp and Pembrolizumab for Patients with Previously Treated Advanced Melanoma

Metastatic malignant melanoma

Methoxsalen (ECP) versus drug combination for steroid‑refractory immune‑related colitis or hepatitis in metastatic melanoma on checkpoint therapy

Metastatic malignant melanoma+2

Study of local treatment options for large metastases in patients with BRAF V600 mutated melanoma receiving Encorafenib and Binimetinib combination therapy

Metastatic malignant melanoma

Study on the Effectiveness of Enfortumab Vedotin and Pembrolizumab for Patients with Advanced Melanoma

Metastatic malignant melanoma

Study of BI-1607, Ipilimumab, and Pembrolizumab for Patients with Advanced Melanoma

Metastatic malignant melanoma

Study Comparing ABP 206 and Nivolumab for Patients with Unresectable or Metastatic Melanoma

Metastatic malignant melanoma

Study on Dacarbazine, Pembrolizumab, Nivolumab, and Ipilimumab for Patients with Unresectable or Metastatic Melanoma Resistant to Immunotherapy

Explore other searches

Vaccine trials

Paediatric trials · ages 0–17

Healthy volunteers

Helpful resources

How applying through us works

What happens after you apply

Guides for patients and volunteers

Search filters

Prefer not to search? Our Concierge searches the trials for you.